NCT01720901View on ClinicalTrials.gov

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

PHASE4SuspendedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Icotinib

Icotinib will be administered 250 mg one time by month, 3 times per day.

Trial Locations (1)

410008

Xiangya Hospital, Central-South Univercity, Changsha

Sponsors
All Listed Sponsors
lead

Betta Pharmaceuticals Co., Ltd.

INDUSTRY